Trending...
- Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
- LARUS Launches Business Continuity Framework for IPv4-Dependent Networks
- Evolve Construction Mobilizes Commercial Storm Response Across Illinois With AI-Powered Damage Documentation and Public Adjusters Partnership
LAS VEGAS, Dec. 31, 2021 /PRNewswire/ -- iMediSync is launching their revolutionary, comprehensive, early mental health diagnostics and remote care solution, iSyncWave™, after 10-years of research and clinical trials.
iMediSync will offer free 10-minute brain screening sessions throughout their press conference and VIP Tour Program at CES 2022. CES attendees can expect a complete analysis report of their measured EEG (brainwaves) and HRV (heart rate variability). In just ten minutes, early signs of multiple mental conditions and impairments of their brains that are not detectable by conventional methods will be analyzed (such as Alzheimer's dementia). Click here to learn more.
When: January 5th at the iMediSync booth and the CES provided conference room on January 6th.
Who should attend: Media, CES attendees interested in AI health technologies, healthcare professionals, researchers, and pharma companies interested in brain reaction to intervention.
More on nvtip.com
Where: Health & Wellness zone, Tech East-North Hall of Las Vegas Convention Center. LVCC, North Hall - 8455. Las Vegas Westgate Resort & Casino. 3000 Paradise Rd, Las Vegas, NV 89109.
ABOUT iMediSync, Inc.
HEADQUARTERED in Seoul, Korea iMediSync was founded by CEO, Dr. Seung Wan Kang. iMediSync has developed an AI-driven early detection and therapeutic platform for optimal brain health. iMediSync launched its first solution to detect Mild Cognitive Impairment (early stage of Alzheimer's Disease) based on its proprietary EEG database in Korea and other parts of the world. Clinical trials with multicenter hospitals confirmed a 90%+ accuracy for its solution. The vision of iMediSync is to develop early-detecting biomarkers for challenging neurological disorders and diseases such as COMA, Parkinson's, ADHD, Depression, etc. For more information, visit www.imedisync.com.
Media Contact:
Photos and interviews can be arranged per your request.
Aditi Maheshwari
(415) 802-4230
[email protected]
SOURCE iMediSync
iMediSync will offer free 10-minute brain screening sessions throughout their press conference and VIP Tour Program at CES 2022. CES attendees can expect a complete analysis report of their measured EEG (brainwaves) and HRV (heart rate variability). In just ten minutes, early signs of multiple mental conditions and impairments of their brains that are not detectable by conventional methods will be analyzed (such as Alzheimer's dementia). Click here to learn more.
When: January 5th at the iMediSync booth and the CES provided conference room on January 6th.
Who should attend: Media, CES attendees interested in AI health technologies, healthcare professionals, researchers, and pharma companies interested in brain reaction to intervention.
More on nvtip.com
- Tuckwell Machinery Expands CNC Range to Support Australian Cabinet Makers
- The Inner Power of Emotional Self-Leadership
- Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
- Molly Zelvonberger Bridges the Gap Between Complex Legal Theory and Everyday Reality
- Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
Where: Health & Wellness zone, Tech East-North Hall of Las Vegas Convention Center. LVCC, North Hall - 8455. Las Vegas Westgate Resort & Casino. 3000 Paradise Rd, Las Vegas, NV 89109.
ABOUT iMediSync, Inc.
HEADQUARTERED in Seoul, Korea iMediSync was founded by CEO, Dr. Seung Wan Kang. iMediSync has developed an AI-driven early detection and therapeutic platform for optimal brain health. iMediSync launched its first solution to detect Mild Cognitive Impairment (early stage of Alzheimer's Disease) based on its proprietary EEG database in Korea and other parts of the world. Clinical trials with multicenter hospitals confirmed a 90%+ accuracy for its solution. The vision of iMediSync is to develop early-detecting biomarkers for challenging neurological disorders and diseases such as COMA, Parkinson's, ADHD, Depression, etc. For more information, visit www.imedisync.com.
Media Contact:
Photos and interviews can be arranged per your request.
Aditi Maheshwari
(415) 802-4230
[email protected]
SOURCE iMediSync
0 Comments
Latest on nvtip.com
- Genpak Announces Closure of Utah Manufacturing Facility
- Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap
- The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
- Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
- Jeff Miller Challenges Status Quo in June 9th Democratic Primary for Clark County Clerk
- Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
- New Book Reveals The Science Of Predictions
- Beyond Chatbots: VegasAilure Founder Outlines Vision for Verified AI Travel Planning in Las Vegas
- Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
- Colony Ridge Communities Celebrates Successful Soccer Season Kickoff with Families and Youth
- NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
- EFA Announces 2026 Editorial Rate Chart
- Red5 Taps PubNub to Power the Next Era of Real-Time Interactive Streaming
- Shoutout Joseph Neibich aka Nybyk
- Meet Joseph Neibich aka Joseph Nybyk of Beachwood Canyon
- LARUS Launches Business Continuity Framework for IPv4-Dependent Networks
- KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
- Nick Perkins, Chief Strategy Officer of The Digital Ring, Establishes Scalable Growth for Businesses
- Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
